PRESS TO LISTEN TO AUDIO
Clara is a 62 year old patient with a complex past history. About 20 years ago, she had an early stage cervical cancer removed. Now she presents with masses in her peritoneum/abdomen from the original cervical cancer.
Her oncologist had limited experience with the treatment of this type of cancer. He welcomed a second opinion. The team at Rupert Case Management (RCM) provided two second opinions from world class gynecological oncologists. One of the experts suggested that we consider molecular profiling. That is when this scientific advance became very important for Clara.
Molecular profiling is a new diagnostic technology. Each cancer has a unique signature. The signature can be de-coded using biomarker testing. Then the patient’s biomarker signature is used to search the world’s medical literature for treatment options based on world wide biomarker research. This search generates an evidence-based treatment protocol . This is revolutionary for cancer patients.
Molecular profiling begins with an immuno-histochemistry (IHC) analysis. An IHC test measures the level of important proteins in cancer cells providing clues about which therapies are likely to have clinical benefit and then what additional tests should be run.
With a sample of patient tissue, then a gene expression analysis can be done using a microarray. The microarray test looks for genes in the tumor that are associated with specific treatment options.
As deemed appropriate, additional tests such as Fluorescent In-Situ Hybridization (FISH) is used to examine gene copy number variation in the tumor. Polymerase Chain Reaction (PCR) or DNA sequencing is used to determine gene mutations in the tumor DNA.
The results from each of these tests are matched with the published findings from thousands of the world’s leading cancer researchers. Based on this analysis, the process identifies potential therapies for patients and their treating physicians to discuss.
This is an important starting point for Clara and her team of doctors.
Molecular profiling is available for patients requiring chemotherapy. The process of selecting medications is very complex. At times, the process is subjective and is based on a doctor’s personal experience and his/her interpretation of the medical literature.
The team at RCM will be pleased to assist clients in ordering molecular profiling and co-ordinating all aspects of the process from start to resolution.
To start the conversation, call at any time. 1- 800 620 7551.